Lenvatinib is a synthetic, orally available inhibitor of VEGFR2 tyrosine kinase with potential antineoplastic activity.

Apatinib is an orally bioavailable, selective VEGFR2 inhibitor.

Lapatinib Ditosylate is a tyrosine kinase receptor inhibitor used in the therapy of advanced breast cancer and other solid tumors.

Erlotinib hydrochloride is a quinazoline derivative and antineoplastic agent that functions as a protein kinase inhibitor for EGFR associated tyrosine kinase.

AP26113-analog (ALK-IN-1) is an analog of AP26113 which is a potent and selective ALK inhibitor. It is also an inhibitor of EGFR.

Neratinib is a irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential antineoplastic activity, and also a P-Glycoprotein Inhibitor.

Ceritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity.

Crizotinib is an orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity.